The treatment of behavioural and psychological symptoms in dementia: pragmatic recommendations
Geneva Memory Centre / LANVIE · 2024 · Switzerland
Source and licence
- Authors
- Camille Mercier, Victoria Rollason, Mohamed Eshmawey et al.
- Title
- The treatment of behavioural and psychological symptoms in dementia: pragmatic recommendations
- Journal
- Psychogeriatrics, 2024
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC11578037
Licence statement of the original publication
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.
Abstract
Behavioural and psychological symptoms of dementia (BPSD) are a clinical challenge for the lack of a sound taxonomy, frequent presentation with comorbid BPSD, lack of specific pharmacologic interventions, poor base of methodologically sound evidence with randomized clinical trials, contamination from the treatment of behavioural disturbances of young and adult psychiatric conditions, and small efficacy window of psychotropic drugs. We present here a treatment workflow based on a concept‐driven literature review based on the notions that (i) the aetiology of BPSD can be mainly neurobiological (so‐called ‘primary’ symptoms) or mainly environmental and functional (‘secondary’ symptoms) and that this drives treatment; (ii) the clinical efficacy of psychotropic drugs is driven by their specific profile of receptor affinity; (iii) drug treatment should follow the rules of ‘start low–go slow, prescribe and revise’. This article argues in support of the distinction between primary and secondary BPSD, as well as their characteristics, which until now have been just sketchily described in the literature. It also offers comprehensive and pragmatic clinician‐oriented recommendations for the treatment of BPSD.
Contents of the original publication
The section headings of the original.
- INTRODUCTION AND AIM
- PATHOPHYSIOLOGY
- TREATMENT: BASIC RECOMMENDATIONS
- NON‐PHARMACOLOGICAL TREATMENT
- PHARMACOLOGICAL TREATMENT
- FUTURE PROSPECTS AND CONCLUSIONS
- Supporting information
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint